ID   TRPM6_HUMAN             Reviewed;        2022 AA.
AC   Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 2.
DT   12-OCT-2022, entry version 168.
DE   RecName: Full=Transient receptor potential cation channel subfamily M member 6;
DE            EC=2.7.11.1;
DE   AltName: Full=Channel kinase 2;
DE   AltName: Full=Melastatin-related TRP cation channel 6;
GN   Name=TRPM6; Synonyms=CHAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND CHARACTERIZATION.
RC   TISSUE=Kidney;
RX   PubMed=11357414;
RA   Riazanova L.V., Pavur K.S., Petrov A.N., Dorovkov M.V., Riazanov A.G.;
RT   "Novel type of signaling molecules: protein kinases covalently linked to
RT   ion channels.";
RL   Mol. Biol. (Mosk.) 35:321-332(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND VARIANT HOMG1 LEU-141.
RC   TISSUE=Kidney, and Small intestine;
RX   PubMed=12032568; DOI=10.1038/ng889;
RA   Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L.N., Vitzthum H.,
RA   Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D., Syrrou M.,
RA   Nielsen S., Sassen M.C., Waldegger S., Seyberth H.W., Konrad M.;
RT   "Hypomagnesemia with secondary hypocalcemia is caused by mutations in
RT   TRPM6, a new member of the TRPM gene family.";
RL   Nat. Genet. 31:166-170(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRPM6A; TRPM6B; TRPM6C; TRPM6T;
RP   M6-KINASE 1; M6-KINASE 2 AND M6-KINASE 3), CHARACTERIZATION OF VARIANT
RP   HOMG1 LEU-141, AND INTERACTION WITH TRPM7.
RC   TISSUE=Lung cancer;
RX   PubMed=14976260; DOI=10.1073/pnas.0305252101;
RA   Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H.,
RA   Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.;
RT   "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6
RT   gene causes hypomagnesemia with secondary hypocalcemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   INTERACTION WITH RACK1, PHOSPHORYLATION AT THR-1851, AND MUTAGENESIS OF
RP   LYS-1804 AND THR-1851.
RX   PubMed=18258429; DOI=10.1016/j.cub.2007.12.058;
RA   Cao G., Thebault S., van der Wijst J., van der Kemp A., Lasonder E.,
RA   Bindels R.J., Hoenderop J.G.;
RT   "RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha-
RT   kinase domain.";
RL   Curr. Biol. 18:168-176(2008).
RN   [6]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-75; ILE-338; CYS-1007; ARG-1243;
RP   ARG-1274; ILE-1393; GLU-1584; ARG-1663; SER-1673 AND ILE-1724.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [7]
RP   VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; PRO-1143 AND ASN-1754, VARIANT
RP   ARG-1663, CHARACTERIZATION OF VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053;
RP   PRO-1143 AND ASN-1754, CHARACTERIZATION OF VARIANT ARG-1663, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=23942199; DOI=10.1038/ejhg.2013.178;
RA   Lainez S., Schlingmann K.P., van der Wijst J., Dworniczak B.,
RA   van Zeeland F., Konrad M., Bindels R.J., Hoenderop J.G.;
RT   "New TRPM6 missense mutations linked to hypomagnesemia with secondary
RT   hypocalcemia.";
RL   Eur. J. Hum. Genet. 22:497-504(2014).
CC   -!- FUNCTION: Essential ion channel and serine/threonine-protein kinase.
CC       Crucial for magnesium homeostasis. Has an important role in epithelial
CC       magnesium transport and in the active magnesium absorption in the gut
CC       and kidney. Isoforms of the type M6-kinase lack the ion channel region.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Forms heterodimers with TRPM7. TRPM6 requires the presence of
CC       TRPM7 to be targeted to the cell membrane (in HEK 293 cells). Interacts
CC       (via kinase domain) with RACK1. {ECO:0000269|PubMed:14976260,
CC       ECO:0000269|PubMed:18258429}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23942199};
CC       Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=TRPM6a;
CC         IsoId=Q9BX84-1; Sequence=Displayed;
CC       Name=TRPM6b;
CC         IsoId=Q9BX84-2; Sequence=VSP_012069;
CC       Name=TRPM6c;
CC         IsoId=Q9BX84-3; Sequence=VSP_012070;
CC       Name=TRPM6t;
CC         IsoId=Q9BX84-4; Sequence=VSP_012075, VSP_012076;
CC       Name=M6-kinase 1;
CC         IsoId=Q9BX84-5; Sequence=VSP_012074;
CC       Name=M6-kinase 2;
CC         IsoId=Q9BX84-6; Sequence=VSP_012073;
CC       Name=M6-kinase 3;
CC         IsoId=Q9BX84-7; Sequence=VSP_012071, VSP_012072;
CC   -!- TISSUE SPECIFICITY: Highly expressed in kidney and colon. Isoform
CC       TRPM6a and isoform TRPM6b, are coexpressed with TRPM7 in kidney, and
CC       testis, and are also found in several cell lines of lung origin.
CC       Isoform TRPM6c is detected only in testis and in NCI-H510A small cell
CC       lung carcinoma cells.
CC   -!- DISEASE: Hypomagnesemia 1 (HOMG1) [MIM:602014]: A disorder due to a
CC       primary defect in intestinal magnesium absorption. It is characterized
CC       by low levels of serum magnesium alongside with a normal renal
CC       magnesium secretion, secondary hypocalcemia and calcinocis. Affected
CC       individuals show neurologic symptoms of hypomagnesemic hypocalcemia,
CC       including seizures and muscle spasms, during infancy. Hypocalcemia is
CC       secondary to parathyroid failure resulting from magnesium deficiency.
CC       Untreated, the disorder may be fatal or may result in neurological
CC       damage. {ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260,
CC       ECO:0000269|PubMed:23942199}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform M6-kinase 1]: Lacks the ion channel region.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform M6-kinase 2]: Lacks the ion channel region.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform M6-kinase 3]: Lacks the ion channel region.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase
CC       superfamily. Alpha-type protein kinase family. ALPK subfamily.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the transient
CC       receptor (TC 1.A.4) family. LTrpC subfamily. TRPM6 sub-subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF350881; AAK31202.2; -; mRNA.
DR   EMBL; AF448232; AAM21562.1; -; mRNA.
DR   EMBL; AY333282; AAR03487.1; -; mRNA.
DR   EMBL; AY333283; AAR03488.1; -; mRNA.
DR   EMBL; AY333284; AAR03489.1; -; mRNA.
DR   EMBL; AY333285; AAR03490.1; -; mRNA.
DR   EMBL; AY333286; AAR03491.1; -; mRNA.
DR   EMBL; AY333287; AAR03492.1; -; mRNA.
DR   EMBL; AY333288; AAR03493.1; -; mRNA.
DR   EMBL; AL354795; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS55318.1; -. [Q9BX84-3]
DR   CCDS; CCDS55319.1; -. [Q9BX84-2]
DR   CCDS; CCDS6647.1; -. [Q9BX84-1]
DR   RefSeq; NP_001170781.1; NM_001177310.1. [Q9BX84-2]
DR   RefSeq; NP_001170782.1; NM_001177311.1. [Q9BX84-3]
DR   RefSeq; NP_060132.3; NM_017662.4. [Q9BX84-1]
DR   AlphaFoldDB; Q9BX84; -.
DR   SMR; Q9BX84; -.
DR   BioGRID; 126713; 1.
DR   CORUM; Q9BX84; -.
DR   IntAct; Q9BX84; 3.
DR   MINT; Q9BX84; -.
DR   STRING; 9606.ENSP00000354006; -.
DR   BindingDB; Q9BX84; -.
DR   ChEMBL; CHEMBL1628470; -.
DR   DrugBank; DB14513; Magnesium.
DR   DrugBank; DB09481; Magnesium carbonate.
DR   GuidetoPHARMACOLOGY; 498; -.
DR   TCDB; 1.A.4.5.8; the transient receptor potential ca2+ channel (trp-cc) family.
DR   iPTMnet; Q9BX84; -.
DR   PhosphoSitePlus; Q9BX84; -.
DR   BioMuta; TRPM6; -.
DR   DMDM; 56404951; -.
DR   EPD; Q9BX84; -.
DR   MassIVE; Q9BX84; -.
DR   MaxQB; Q9BX84; -.
DR   PaxDb; Q9BX84; -.
DR   PeptideAtlas; Q9BX84; -.
DR   PRIDE; Q9BX84; -.
DR   ProteomicsDB; 79380; -. [Q9BX84-1]
DR   ProteomicsDB; 79381; -. [Q9BX84-2]
DR   ProteomicsDB; 79382; -. [Q9BX84-3]
DR   ProteomicsDB; 79383; -. [Q9BX84-4]
DR   ProteomicsDB; 79384; -. [Q9BX84-5]
DR   ProteomicsDB; 79385; -. [Q9BX84-6]
DR   ProteomicsDB; 79386; -. [Q9BX84-7]
DR   ABCD; Q9BX84; 1 sequenced antibody.
DR   Antibodypedia; 2049; 142 antibodies from 24 providers.
DR   DNASU; 140803; -.
DR   Ensembl; ENST00000360774.6; ENSP00000354006.1; ENSG00000119121.22. [Q9BX84-1]
DR   Ensembl; ENST00000361255.7; ENSP00000354962.3; ENSG00000119121.22. [Q9BX84-3]
DR   Ensembl; ENST00000449912.6; ENSP00000396672.2; ENSG00000119121.22. [Q9BX84-2]
DR   GeneID; 140803; -.
DR   KEGG; hsa:140803; -.
DR   MANE-Select; ENST00000360774.6; ENSP00000354006.1; NM_017662.5; NP_060132.3.
DR   UCSC; uc004ajk.1; human. [Q9BX84-1]
DR   CTD; 140803; -.
DR   DisGeNET; 140803; -.
DR   GeneCards; TRPM6; -.
DR   HGNC; HGNC:17995; TRPM6.
DR   HPA; ENSG00000119121; Group enriched (brain, intestine).
DR   MalaCards; TRPM6; -.
DR   MIM; 602014; phenotype.
DR   MIM; 607009; gene.
DR   neXtProt; NX_Q9BX84; -.
DR   OpenTargets; ENSG00000119121; -.
DR   Orphanet; 30924; Primary hypomagnesemia with secondary hypocalcemia.
DR   PharmGKB; PA38479; -.
DR   VEuPathDB; HostDB:ENSG00000119121; -.
DR   eggNOG; KOG3614; Eukaryota.
DR   GeneTree; ENSGT00940000158164; -.
DR   HOGENOM; CLU_001390_2_0_1; -.
DR   InParanoid; Q9BX84; -.
DR   OMA; KIHSCSR; -.
DR   OrthoDB; 738147at2759; -.
DR   PhylomeDB; Q9BX84; -.
DR   TreeFam; TF314204; -.
DR   PathwayCommons; Q9BX84; -.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   SignaLink; Q9BX84; -.
DR   SIGNOR; Q9BX84; -.
DR   BioGRID-ORCS; 140803; 7 hits in 1104 CRISPR screens.
DR   ChiTaRS; TRPM6; human.
DR   GeneWiki; TRPM6; -.
DR   GenomeRNAi; 140803; -.
DR   Pharos; Q9BX84; Tchem.
DR   PRO; PR:Q9BX84; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q9BX84; protein.
DR   Bgee; ENSG00000119121; Expressed in colonic mucosa and 124 other tissues.
DR   ExpressionAtlas; Q9BX84; baseline and differential.
DR   Genevisible; Q9BX84; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005262; F:calcium channel activity; TAS:Reactome.
DR   GO; GO:0005261; F:cation channel activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0098655; P:cation transmembrane transport; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   Gene3D; 1.20.5.1010; -; 1.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR004166; MHCK_EF2_kinase.
DR   InterPro; IPR029597; TRPM6.
DR   InterPro; IPR041491; TRPM_SLOG.
DR   InterPro; IPR032415; TRPM_tetra.
DR   InterPro; IPR037162; TRPM_tetra_sf.
DR   PANTHER; PTHR13800:SF15; PTHR13800:SF15; 1.
DR   Pfam; PF02816; Alpha_kinase; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF18139; LSDAT_euk; 1.
DR   Pfam; PF16519; TRPM_tetra; 1.
DR   SMART; SM00811; Alpha_kinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51158; ALPHA_KINASE; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Calcium; Calcium channel;
KW   Calcium transport; Cell membrane; Disease variant; Ion channel;
KW   Ion transport; Kinase; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Primary hypomagnesemia; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Transmembrane;
KW   Transmembrane helix; Transport; Zinc.
FT   CHAIN           1..2022
FT                   /note="Transient receptor potential cation channel
FT                   subfamily M member 6"
FT                   /id="PRO_0000215329"
FT   TOPO_DOM        1..741
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        742..762
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        763..841
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        842..862
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        863..905
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        906..926
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        927..939
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        940..960
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        961..972
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        973..993
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        994..1012
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        1013..1033
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1034..1047
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1048..1068
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1069..2022
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1750..1980
FT                   /note="Alpha-type protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00501"
FT   REGION          1479..1516
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1997..2022
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1491..1516
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2002..2022
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1923
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         1780
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1804
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1876
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1909
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1925
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1933
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1950..1956
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1966
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1968
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1972
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1851
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18258429"
FT   VAR_SEQ         1..11
FT                   /note="MKEQPVLERLQ -> MIILSK (in isoform TRPM6b)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012069"
FT   VAR_SEQ         1..11
FT                   /note="MKEQPVLERLQ -> MTAPVT (in isoform TRPM6c)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012070"
FT   VAR_SEQ         281
FT                   /note="R -> P (in isoform M6-kinase 3)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012071"
FT   VAR_SEQ         282..1734
FT                   /note="Missing (in isoform M6-kinase 3)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012072"
FT   VAR_SEQ         500..1666
FT                   /note="Missing (in isoform M6-kinase 2)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012073"
FT   VAR_SEQ         547..1595
FT                   /note="Missing (in isoform M6-kinase 1)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012074"
FT   VAR_SEQ         1926..1943
FT                   /note="GVGENLTDPSVIKPEVKQ -> ALWFWDSMLKARLGGWRM (in isoform
FT                   TRPM6t)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012075"
FT   VAR_SEQ         1944..2022
FT                   /note="Missing (in isoform TRPM6t)"
FT                   /evidence="ECO:0000303|PubMed:14976260"
FT                   /id="VSP_012076"
FT   VARIANT         75
FT                   /note="G -> V (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1193127627)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042387"
FT   VARIANT         141
FT                   /note="S -> L (in HOMG1; impairs heterodimer formation
FT                   resulting in intracellular retention; dbSNP:rs121912625)"
FT                   /evidence="ECO:0000269|PubMed:12032568,
FT                   ECO:0000269|PubMed:14976260"
FT                   /id="VAR_019963"
FT   VARIANT         338
FT                   /note="M -> I (in dbSNP:rs56155062)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042388"
FT   VARIANT         708
FT                   /note="L -> P (in HOMG1; loss of function; no effect on
FT                   cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:23942199"
FT                   /id="VAR_071480"
FT   VARIANT         872
FT                   /note="E -> G (in HOMG1; loss of function; no effect on
FT                   cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:23942199"
FT                   /id="VAR_071481"
FT   VARIANT         948
FT                   /note="F -> L (in dbSNP:rs13290391)"
FT                   /id="VAR_052380"
FT   VARIANT         1007
FT                   /note="W -> C (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042389"
FT   VARIANT         1053
FT                   /note="Y -> C (in HOMG1; loss of function; no effect on
FT                   cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:23942199"
FT                   /id="VAR_071482"
FT   VARIANT         1071
FT                   /note="N -> D (in dbSNP:rs2274922)"
FT                   /id="VAR_019964"
FT   VARIANT         1143
FT                   /note="L -> P (in HOMG1; loss of function; no effect on
FT                   cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:23942199"
FT                   /id="VAR_071483"
FT   VARIANT         1243
FT                   /note="H -> R (in dbSNP:rs55694430)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042390"
FT   VARIANT         1274
FT                   /note="Q -> R (in dbSNP:rs34608911)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042391"
FT   VARIANT         1393
FT                   /note="V -> I (in dbSNP:rs3750425)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_019965"
FT   VARIANT         1584
FT                   /note="K -> E (in dbSNP:rs2274924)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_019966"
FT   VARIANT         1663
FT                   /note="Q -> R (no effect on function or cell membrane
FT                   localization; dbSNP:rs55679040)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:23942199"
FT                   /id="VAR_042392"
FT   VARIANT         1673
FT                   /note="L -> S (in dbSNP:rs56254742)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042393"
FT   VARIANT         1724
FT                   /note="T -> I (in dbSNP:rs56290308)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042394"
FT   VARIANT         1754
FT                   /note="S -> N (in HOMG1; loss of function; no effect on
FT                   cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:23942199"
FT                   /id="VAR_071484"
FT   MUTAGEN         1804
FT                   /note="K->R: Abolishes kinase activity but does not affect
FT                   expression levels or binding to RACK1."
FT                   /evidence="ECO:0000269|PubMed:18258429"
FT   MUTAGEN         1851
FT                   /note="T->A: Significantly decreases autophosphorylation.
FT                   Does not alter binding to RACK1 but prevents inhibition by
FT                   RACK1."
FT                   /evidence="ECO:0000269|PubMed:18258429"
FT   MUTAGEN         1851
FT                   /note="T->D: Significantly decreases autophosphorylation.
FT                   Does not alter binding to RACK1 or inhibition by RACK1."
FT                   /evidence="ECO:0000269|PubMed:18258429"
SQ   SEQUENCE   2022 AA;  231708 MW;  59346B3BE3300466 CRC64;
     MKEQPVLERL QSQKSWIKGV FDKRECSTII PSSKNPHRCT PVCQVCQNLI RCYCGRLIGD
     HAGIDYSWTI SAAKGKESEQ WSVEKHTTKS PTDTFGTINF QDGEHTHHAK YIRTSYDTKL
     DHLLHLMLKE WKMELPKLVI SVHGGIQNFT MPSKFKEIFS QGLVKAAETT GAWIITEGIN
     TGVSKHVGDA LKSHSSHSLR KIWTVGIPPW GVIENQRDLI GKDVVCLYQT LDNPLSKLTT
     LNSMHSHFIL SDDGTVGKYG NEMKLRRNLE KYLSLQKIHC RSRQGVPVVG LVVEGGPNVI
     LSVWETVKDK DPVVVCEGTG RAADLLAFTH KHLADEGMLR PQVKEEIICM IQNTFNFSLK
     QSKHLFQILM ECMVHRDCIT IFDADSEEQQ DLDLAILTAL LKGTNLSASE QLNLAMAWDR
     VDIAKKHILI YEQHWKPDAL EQAMSDALVM DRVDFVKLLI EYGVNLHRFL TIPRLEELYN
     TKQGPTNTLL HHLVQDVKQH TLLSGYRITL IDIGLVVEYL IGRAYRSNYT RKHFRALYNN
     LYRKYKHQRH SSGNRNESAE STLHSQFIRT AQPYKFKEKS IVLHKSRKKS KEQNVSDDPE
     STGFLYPYND LLVWAVLMKR QKMAMFFWQH GEEATVKAVI ACILYRAMAH EAKESHMVDD
     ASEELKNYSK QFGQLALDLL EKAFKQNERM AMTLLTYELR NWSNSTCLKL AVSGGLRPFV
     SHTCTQMLLT DMWMGRLKMR KNSWLKIIIS IILPPTILTL EFKSKAEMSH VPQSQDFQFM
     WYYSDQNASS SKESASVKEY DLERGHDEKL DENQHFGLES GHQHLPWTRK VYEFYSAPIV
     KFWFYTMAYL AFLMLFTYTV LVEMQPQPSV QEWLVSIYIF TNAIEVVREI CISEPGKFTQ
     KVKVWISEYW NLTETVAIGL FSAGFVLRWG DPPFHTAGRL IYCIDIIFWF SRLLDFFAVN
     QHAGPYVTMI AKMTANMFYI VIIMAIVLLS FGVARKAILS PKEPPSWSLA RDIVFEPYWM
     IYGEVYAGEI DVCSSQPSCP PGSFLTPFLQ AVYLFVQYII MVNLLIAFFN NVYLDMESIS
     NNLWKYNRYR YIMTYHEKPW LPPPLILLSH VGLLLRRLCC HRAPHDQEEG DVGLKLYLSK
     EDLKKLHDFE EQCVEKYFHE KMEDVNCSCE ERIRVTSERV TEMYFQLKEM NEKVSFIKDS
     LLSLDSQVGH LQDLSALTVD TLKVLSAVDT LQEDEALLAK RKHSTCKKLP HSWSNVICAE
     VLGSMEIAGE KKYQYYSMPS SLLRSLAGGR HPPRVQRGAL LEITNSKREA TNVRNDQERQ
     ETQSSIVVSG VSPNRQAHSK YGQFLLVPSN LKRVPFSAET VLPLSRPSVP DVLATEQDIQ
     TEVLVHLTGQ TPVVSDWASV DEPKEKHEPI AHLLDGQDKA EQVLPTLSCT PEPMTMSSPL
     SQAKIMQTGG GYVNWAFSEG DETGVFSIKK KWQTCLPSTC DSDSSRSEQH QKQAQDSSLS
     DNSTRSAQSS ECSEVGPWLQ PNTSFWINPL RRYRPFARSH SFRFHKEEKL MKICKIKNLS
     GSSEIGQGAW VKAKMLTKDR RLSKKKKNTQ GLQVPIITVN ACSQSDQLNP EPGENSISEE
     EYSKNWFTVS KFSHTGVEPY IHQKMKTKEI GQCAIQISDY LKQSQEDLSK NSLWNSRSTN
     LNRNSLLKSS IGVDKISASL KSPQEPHHHY SAIERNNLMR LSQTIPFTPV QLFAGEEITV
     YRLEESSPLN LDKSMSSWSQ RGRAAMIQVL SREEMDGGLR KAMRVVSTWS EDDILKPGQV
     FIVKSFLPEV VRTWHKIFQE STVLHLCLRE IQQQRAAQKL IYTFNQVKPQ TIPYTPRFLE
     VFLIYCHSAN QWLTIEKYMT GEFRKYNNNN GDEITPTNTL EELMLAFSHW TYEYTRGELL
     VLDLQGVGEN LTDPSVIKPE VKQSRGMVFG PANLGEDAIR NFIAKHHCNS CCRKLKLPDL
     KRNDYSPERI NSTFGLEIKI ESAEEPPARE TGRNSPEDDM QL
//
